A Regional Monoclonal Antibody Infusion Treatment Center will be located in Nash Texas at 401 Industrial Boulevard and is expected to be operational within a week and offering the treatment known as “Regeneron” in the battle against COVID 19.
Press Release:
Judge Bobby Howell and Texarkana, Texas Mayor Bob Bruggeman received notification this week from the Texas Department of Emergency Management that Texarkana has been chosen as a site for a regional monoclonal antibody infusion treatment center in the battle against COVID-19.
It is anticipated that the site will be operational within the week, and is located at 401 Industrial Boulevard, Nash, TX.
While the treatment is an outpatient process, patients must have a physician’s order to seek the antibody infusion, called Regeneron.
Patients are a candidate for the treatment if they meet one or more of the following criteria:
- 65 years of age or older
- Obesity or being overweight
- Pregnancy
- Chronic Kidney Disease
- Diabetes
- Immunosuppressive Disease
- Receiving Immunosuppressive Treatment
- Cardiovascular disease or hypertension
- Chronic lung diseases
- Sickle Cell Disease
- Neurodevelopmental disorders or other conditions that confer medical complexity
- Having a medical-related technological dependence
If you have received a positive COVID-19 result and think you may be a candidate for this treatment, please consult your physician.
The treatment is not authorized for patients who are hospitalized due to COVID-19, who require oxygen therapy due to COVID-19, or who require an increase in baseline oxygen flow rate due to COVID-19 in those on chronic oxygen therapy due to underlying non-COVID-19 related comorbidity.
